MONDAY

IMS Welcome Reception and Buffet

TUESDAY

Opening Ceremony
Welcoming Remarks
Host Association Verband Forschender Arzneimittelhersteller e. V. – VFA,
Senior Government Official from Germany

Introductory remarks by the President of IFPMA
Prof. Dr. Rolf Krebs, Chairman, Boehringer Ingelheim GmbH,
Germany and President IFPMA

Overview of Issues
Dr. Harvey E. Bale, Jr., Director General, IFPMA

Session 1 – Encouraging Innovation
Chairperson – Dr. Francis Gurry, Assistant Director General and Legal Counsel, World Intellectual Property Organization (WIPO), Switzerland
Panel Discussion
• Mr. Adrian Otten, Director, Intellectual Property Division, World Trade Organization, Switzerland
• Mr. Paul Vandoren, Head of Unit, New Technologies, Intellectual Property & Public Procurement,
European Commission, Belgium
• Mr. Claude Burcky, Deputy Assistant USTR for Intellectual Property, Office of the US Trade
Representative, USA
• Mr. Francisco Pessanha Cannabrava, Second Secretary, Permanent Mission of Brazil to the United
Nations in Geneva, Switzerland (tbc)
• Mr. Jacques J. Gorlin, The Gorlin Group, USA

Session 2 – The Pharmaceutical Industry and Social Responsibility
Chairperson
Prof. Dr. Klaus M. Leisinger, Executive Director,
Novartis Foundation for Sustainable Development, Switzerland
Panel Discussion
• Prof. Ethan B. Kapstein, Department of Economics & Political Sciences, INSEAD, France
• Mr. Alex Preker, Lead Economist, Human Development Network, The World Bank, USA
• Ms. Marika Fahlen, Director, Social Mobilization & Information Department, UNAIDS, Switzerland
• Prof. Francis P. Crawley, Chairman, Ethics Working Party, European Forum for Good Clinical Practice,
Belgium
• Ms. Sophia Tickell, Senior Policy Advisor, Oxfam, UK
• Mr. Chuck Hardwick, Vice President and Corporate Officer, Pfizer, Inc., USA
General Discussion

LUNCH sponsored by Boehringer Ingelheim GmbH

Session 3 – Strategies for Communicating the Value of the Industry
Chairperson
Dr. Philip Brown, Executive Chairman, PJB Publications, UK
Panel Discussion
• Mr. Alan Holmer, President and Chief Executive Officer, Pharmaceutical Research and Manufacturers
of America – PhRMA, USA
• Mr. Thomas Cueni, Secretary General, Interpharma, Switzerland
• Mr. Stewart Adkins, Managing Director, Senior Pharmaceutical Analyst, Lehman Brothers, UK
• Mr. Roger Bate, Director, International Policy Network, USA
Other panelists to be confirmed
General Discussion

Session 4 – Information/Communication to Patients and Healthcare Professionals
Chairperson
Mr. Per Wold-Olsen, President, Human Health – Europe, Middle East & Africa,
Merck & Co., Inc., USA
Panel Discussion
• Prof. Dr. Gunther Eysenbach, Associate Professor, Department of Health Policy, Management
and Evaluation, University of Toronto, Canada (tbc)
• Mr. Filippo von Schloesser, Chairman of the Board, European AIDS Treatment Group, Germany
Other panelists to be confirmed
General Discussion

WEDNESDAY

Session 5 – The Future of the Pharmaceutical Industry in the Major Markets
Chairperson
Dr. George Poste, Chief Executive Officer, Health Technology Networks, USA
Panel Discussion
• Dr. Philippe Pouletty, Président, France Biotech, France
• Mr. Gilles Pajot, Executive Vice President and President for Europe, IMS, UK
Other panelists to be confirmed
General Discussion

Session 6 – New Partnerships and Ways of Operating to Improve Public Health
Chairperson
Dr. Ok Pannenborg, Senior Health Advisor, The World Bank, USA
Panel Discussion
• Dr. Crispus Kiyonga, Minister Government of Uganda and Interim Chairman and Board Member of
The Global Fund to Fight AIDS, Tuberculosis & Malaria
• Mr. Thomas Kubic, Executive Director, Pharmaceutical Security Institute, USA
• Dr. Derek Yach, Executive Director, Noncommunicable Diseases and Mental Health, World Health
Organization, Switzerland
• Dr. Tore Godal, Executive Secretary, Global Alliance for Vaccines and Immunization (GAVI), Switzerland
• Mr. Christopher Murray, Director, Pharma International, Hoffmann-La Roche, Switzerland
Other panelists to be confirmed
General Discussion

Closing Ceremony – Conclusions / Priorities for 2003–2004
Incoming President IFPMA

LUNCH sponsored by Merck & Co., Inc